Can Samsung Bioepis challenge Keytruda after its U.S. patent cliff begins in 2028?
Samsung Bioepis matched Keytruda in Phase 3, but an earlier FDA filing and Keytruda Qlex complicate the coming biosimilar battle.
Features & Analysis